Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.93)
# 586
Out of 5,072 analysts
215
Total ratings
57.48%
Success rate
7.25%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Neutral | $305 → $315 | $342.20 | -7.95% | 18 | Nov 6, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $109.86 | +1.95% | 2 | Oct 31, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $925 → $985 | $1,109.34 | -11.21% | 14 | Oct 31, 2025 | |
| GILD Gilead Sciences | Reiterates: Overweight | $135 | $126.72 | +6.53% | 16 | Oct 31, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $678 → $740 | $784.80 | -5.71% | 21 | Oct 29, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $230.27 | +8.57% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $428.77 | +13.11% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $49.00 | +12.24% | 16 | Apr 23, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $25.69 | -6.58% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $49.71 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $85 | $104.49 | -18.65% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $152.32 | +8.32% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $36.00 | -44.44% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $181.51 | -0.83% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $8.11 | +639.83% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.71 | +321.94% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.16 | +679.22% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $68.16 | +39.38% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $12.34 | +62.07% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $72.10 | +1.25% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.31 | +816.03% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $3.28 | -54.27% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.25 | +800.00% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $163.33 | +132.66% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $105.48 | -22.26% | 5 | Jan 16, 2019 |
Amgen
Nov 6, 2025
Maintains: Neutral
Price Target: $305 → $315
Current: $342.20
Upside: -7.95%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $109.86
Upside: +1.95%
Eli Lilly and Company
Oct 31, 2025
Maintains: Overweight
Price Target: $925 → $985
Current: $1,109.34
Upside: -11.21%
Gilead Sciences
Oct 31, 2025
Reiterates: Overweight
Price Target: $135
Current: $126.72
Upside: +6.53%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Overweight
Price Target: $678 → $740
Current: $784.80
Upside: -5.71%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $230.27
Upside: +8.57%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $428.77
Upside: +13.11%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $49.00
Upside: +12.24%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $25.69
Upside: -6.58%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $49.71
Upside: -
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $104.49
Upside: -18.65%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $152.32
Upside: +8.32%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $36.00
Upside: -44.44%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $181.51
Upside: -0.83%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $8.11
Upside: +639.83%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.71
Upside: +321.94%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.16
Upside: +679.22%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $68.16
Upside: +39.38%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $12.34
Upside: +62.07%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $72.10
Upside: +1.25%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.31
Upside: +816.03%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $3.28
Upside: -54.27%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.25
Upside: +800.00%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $163.33
Upside: +132.66%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $105.48
Upside: -22.26%